A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Incyte Corporation
Incyte Corporation
Incyte Corporation
Stanford University
University of Chicago
AbbVie
OHSU Knight Cancer Institute
Children's Oncology Group